Prospectuses and communications, business combinations



BGCOLOR="WHITE">





Filed by Consonance-HFW Acquisition Corp.



Pursuant to Rule 425 under the Securities Act of 1933



and deemed filed pursuant to Rule 14a-12



of the Securities Exchange Act of 1934




Subject Company: Consonance-HFW Acquisition Corp.



Commission File No. 001-39635




Surrozen Presents New Data Demonstrating Superior Activity of

SZN-1326

in Preclinical Inflammatory




Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organisation (ECCO)




Company to advance

SZN-1326

toward


first-in-human


clinical studies in 2022



SOUTH SAN FRANCISCO, Calif.,
July 09, 2021 (GLOBE NEWSWIRE) – Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced today that new data from its inflammatory bowel disease (IBD) program,
including preclinical studies of

SZN-1326

showing superior activity compared to therapeutics currently used in treatment, were presented during the
16

th

Congress of the European Crohn’s and Colitis Organisation.



Two poster presentations
discussed data from studies of

SZN-1326,

a

bi-specific

full-length human anti




The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Consonance-HFW Acquisition Corp. makes a similar move, sign up!

Other recent filings from the company include the following:

Kevin Livingston just provided an update on activist position in Consonance-HFW Acquisition Corp. - Sept. 29, 2021

Auto Refresh

Feedback